Janssen and Bavarian Nordic sign $836m deal on Hep B and HIV vaccinesJanssen has signed a new deal with Bavarian Nordic worth up to $836 million to develop target vaccines Share XJanssen and Bavarian Nordic sign $836m deal on Hep B and HIV vaccineshttps://pharmaphorum.com/news/janssen-bavarian-nordic-sign-836m-deal-hep-b-hiv-vaccines/
BMS looks to Opdivo + vaccine combo for non-PD-L1 lung cancer patientsBristol-Myers Squibb is teaming up with France’s Transgene to combine Opdivo with investigational therapeutic vaccine TG4010 in lung Share XBMS looks to Opdivo + vaccine combo for non-PD-L1 lung cancer patientshttps://pharmaphorum.com/news/bms-looks-opdivo-cancer-vaccine-combination-regain-ground-nsclc/
